Virtual Library

Start Your Search

Keith Knutson



Author of

  • +

    P2.17 - Treatment of Early Stage/Localized Disease (ID 189)

    • Event: WCLC 2019
    • Type: Poster Viewing in the Exhibit Hall
    • Track: Treatment of Early Stage/Localized Disease
    • Presentations: 1
    • Moderators:
    • Coordinates: 9/09/2019, 10:15 - 18:15, Exhibit Hall
    • +

      P2.17-14 - Impaired Immune Defense in Tumor Micro-Environment Is Associated with Risk of Recurrence in Early Stage Lung Adenocarcinoma (ID 1977)

      10:15 - 18:15  |  Author(s): Keith Knutson

      • Abstract

      Background

      Despite curative surgery with or without chemotherapy, 27-76% of surgically resected early stage lung cancer will unfortunately develop recurrence which is often fatal. Platinum-based adjuvant chemotherapy in NSCLC improves cure rates in only 5% of patients at the cost of significant toxicities. Developing biomarkers to select high risk patients and strategies to reduce recurrence in early stage lung cancer are critical.

      Method

      Thirty surgically resected primary lung adenocarcinomas from 16 patients with lung cancer recurrence and 14 patients without recurrence in 4 years were included in this study. Among these 30 patients, 27 have either stage I or II. RNA sequencing (694 genes and 14 key immuno-oncology (IO) pathways) was determined using nanoString technology and RNA from primary tumors from recurrent versus non-recurrent patients.

      Result

      Chemokines including CCL18, CCL23, CXCL1, CXCL2, CCL26 and chemokine receptors CXCR2, CX3CR1 and TNFRSF10C were significantly decreased in tumors from patients who had recurrence versus those from patients without recurrence. By contrast, genes related to cancer associated fibroblasts in the stromal microenvironment such as LRRC15 and genes involved in release of cancer cell antigens were significantly increased in adenocarcinomas from recurrent patients. picture1.jpg

      Conclusion

      Our results suggest that recurrence in early stage lung adenocarcinoma might be related to impaired immune defense such as decreased immune cell trafficking and antigen release in tumor micro-environment. Further study with larger sample size is warranted.